Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has seen a notable upgrade in its quality grade from average to good, reflecting significant improvements in its business fundamentals. The company’s robust sales and EBIT growth, alongside prudent debt management and enhanced returns on capital, underpin this positive reassessment by MarketsMOJO. Investors should consider these developments in the context of the broader pharmaceuticals sector and Senores’ recent market performance.

Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 21 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.

Senores Pharmaceuticals Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, signalling a shift from an outstanding to a very positive financial trend. Despite recent market headwinds and a 2.9% decline in share price on 21 Jan 2026, the company’s robust revenue growth and margin expansion underscore its strengthening fundamentals within the Pharmaceuticals & Biotechnology sector.

Senores Pharmaceuticals Ltd., a small-cap player in India's pharmaceuticals and biotechnology sector with a market capitalisation of ₹3,691 crores, delivered another quarter of impressive growth in Q3 FY26, though the stock retreated 2.9% on January 20, 2026, to close at ₹783.15. The company reported consolidated net profit of ₹31.66 crores for the quarter ended December 2025, marking an 84.28% year-on-year surge, whilst revenue climbed 69.44% to ₹174.56 crores—the highest quarterly sales figure in the company's recent history.

Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Senores Pharmaceuticals Ltd has surged to a fresh 52-week and all-time high of Rs.876, marking a significant milestone in its stock performance. This new peak reflects robust momentum in the Pharmaceuticals & Biotechnology sector amid a mixed market backdrop.

Senores Pharmaceuticals Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone today by hitting an all-time high of Rs.874.25. This achievement reflects the company’s robust performance and sustained upward momentum in the stock market.

Senores Pharmaceuticals Ltd has reached a significant milestone by hitting a new 52-week and all-time high of Rs.872.6, marking a remarkable rally in the Pharmaceuticals & Biotechnology sector amid a broadly steady market environment.

Senores Pharmaceuticals Ltd has reached a new all-time high, underscoring its robust performance within the Pharmaceuticals & Biotechnology sector. This milestone reflects sustained gains and a positive trajectory in the company’s stock price, supported by strong market dynamics and consistent financial metrics.

Senores Pharmaceuticals Ltd has surged to a fresh 52-week and all-time high of Rs.864.65, marking a significant milestone in its stock performance amid a broadly positive market environment.

Senores Pharmaceuticals Ltd has reached a significant milestone by hitting its all-time high, reflecting robust performance and sustained momentum in the Pharmaceuticals & Biotechnology sector. The stock’s recent surge underscores its resilience and ability to outperform broader market indices.

Senores Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 06 Nov 2025. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 30 December 2025, providing investors with the latest insights into its performance and outlook.

Senores Pharmaceuticals Ltd has reached a significant milestone by hitting a new 52-week high of Rs.849.95, marking a notable surge in its stock price and reflecting strong momentum in the Pharmaceuticals & Biotechnology sector.

Senores Pharmaceuticals Ltd has reached an all-time high of Rs.849.95, underscoring a remarkable phase of growth and resilience in the Pharmaceuticals & Biotechnology sector. This milestone reflects the company’s sustained performance and favourable market positioning over recent periods.

Senores Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.849.65, marking a notable moment in the stock's recent trading activity and reflecting strong momentum within the Pharmaceuticals & Biotechnology sector.